Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y

Core Insights - Utah Medical Products, Inc. (UTMD) shares increased by 2% following the release of its fourth-quarter and full-year 2025 earnings, outperforming the S&P 500 index's 0.2% growth during the same period [1] - Over the past month, UTMD shares rose by 7.6%, significantly exceeding the S&P 500's 1.5% increase [1] Financial Performance - For Q4 2025, UTMD reported earnings per share (EPS) of 80.2 cents, a decrease of 6.3% from 85.7 cents in Q4 2024 [2] - Revenues for the quarter were $9 million, reflecting a 1.2% decline from $9.2 million in the same period a year ago [2] - Gross profit decreased by 1.1% to $5.26 million, down from $5.32 million in Q4 2024 [3] - Operating income fell 16.7% year over year to $2.4 million from $2.9 million, primarily due to increased operating expenses [3] - Net income was $2.6 million, an 11.6% decline from $2.9 million in the prior-year quarter [3] Key Business Metrics - Gross profit margin remained strong at 58.2%, nearly unchanged from 58.1% in the prior-year quarter [4] - Operating income margin declined to 27% from 32%, and net income margin fell to 28.4% from 31.7% [4] - Adjusted consolidated EBITDA for the quarter was $4 million, down 10% from $4.4 million a year ago, with EBITDA as a percentage of sales declining to 43.8% from 48.1% [4] Sales Performance - Domestic U.S. sales in Q4 declined 4.9% to $5.5 million from $5.7 million, with non-Filshie device sales accounting for most of the drop [5] - OEM sales decreased by 31.5% year over year, while Filshie device sales in the U.S. increased by 21.6% [5] - Outside the U.S. sales rose 4.9% to $3.6 million, largely due to favorable foreign exchange rates, but on a constant currency basis, OUS sales were up only 0.5% [5] Management Commentary - Management indicated that the fourth quarter provided a normalized comparison, with no sales to UTMD's China distributor in either Q4 2025 or Q4 2024, allowing margins to stabilize despite cost pressures [6] - Cost-of-living salary increases and raw material inflation continued to impact results, but effective cost containment helped prevent further deterioration [6] Operating Expenses - Operating expenses increased due to higher general and administrative (G&A) costs, including a $0.2 million charge related to an embezzlement case and a $0.4 million write-off tied to cancellation fees [7] - G&A expenses represented 23.2% of sales in Q4, up from 19.3% in the prior-year quarter [7] Factors Influencing Results - Revenue decline was primarily driven by softness in U.S. sales of non-Filshie medical devices and OEM components, with U.S. Filshie sales growth not sufficient to offset declines in other areas [8] - Favorable foreign exchange rates provided a modest benefit to reported international sales, particularly in Europe [8] Legal and Litigation Costs - Legal costs related to product liability litigation increased slightly to $0.4 million from $0.3 million the previous year, with 14 of 19 pending court cases dismissed by the end of January 2026 [9][10] Full-Year Performance - Full-year sales totaled $38.5 million, a 5.8% year-over-year decline from $40.9 million in 2024, with net income falling 18.7% to $11.3 million [11] - EPS dropped 12.1% year over year to $3.48, and gross margin declined to 57.1% from 59% in 2024 [11] Guidance and Future Outlook - Management expects sales to PendoTECH and the China distributor to remain at zero in 2026, aiming to offset losses with new product introductions and organic growth in Filshie sales [12] - There is substantial uncertainty regarding the recovery [12] Share Repurchase and Financial Position - During Q4 2025, UTMD repurchased 17,951 shares at an average cost of $55.35 per share, totaling $1 million [13] - The company ended the year with $85.8 million in cash and investments, up $2.8 million from the end of 2024, and no debt [14]